Skip to main content

Overweight

44
Pipeline Programs
30
Companies
50
Clinical Trials
13 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
22
2
8
0
6
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
3088%
Small Molecule
412%
+ 102 programs with unclassified modality

On Market (6)

Approved therapies currently available

Eli Lilly and Company
MOUNJAROApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
2.4B Part D
Eli Lilly and Company
ZEPBOUNDApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
Eli Lilly and Company
MOUNJARO (AUTOINJECTOR)Approved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Eli Lilly and Company
MOUNJARO KWIKPENApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Eli Lilly and Company
ZEPBOUND (AUTOINJECTOR)Approved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
Eli Lilly and Company
ZEPBOUND KWIKPENApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023

Competitive Landscape

38 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
LY3502970PHASE_1
TirzepatidePHASE_1Peptide
Prevail Therapeutics
15 programs
10
1
4
EloralintidePhase 3Peptide1 trial
EloralintidePhase 3Peptide1 trial
TirzepatidePhase 3Peptide1 trial
TirzepatidePhase 3Peptide1 trial
TirzepatidePhase 2Peptide1 trial
+10 more programs
Active Trials
NCT06916065Completed188Est. Jan 2026
NCT05623839Completed32Est. Jun 2023
NCT06039826Completed46Est. Jul 2024
+12 more trials
Innovent Biologics
2
IBI362Phase 31 trial
IBI362Phase 31 trial
Active Trials
NCT06884293Recruiting470Est. Jun 2027
NCT07469800Not Yet Recruiting336Est. Apr 2027
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
6 programs
2
4
pramlintide acetatePhase 21 trial
pramlintide acetatePhase 21 trial
pramlintide acetatePhase 21 trial
pramlintide acetate 360 mcgPhase 21 trial
AZD7687Phase 11 trial
+1 more programs
Active Trials
NCT01119352Completed45Est. Mar 2011
NCT01207089Completed45Est. Dec 2010
NCT00444561Completed184Est. May 2005
+3 more trials
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
5 programs
1
70 mL red beetroot juicePhase 21 trial
Family Program for the Prevention of Weight GainN/A1 trial
Healthy BabiesN/A1 trial
REx Condition FirstN/A1 trial
Soy groupN/A1 trial
Active Trials
NCT00989170Completed418Est. Dec 2012
NCT01816516Completed546Est. Feb 2014
NCT04300478Completed21Est. Feb 2022
+2 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
1
Amino Acid Drink MixturePhase 21 trial
Active Trials
NCT00974831Completed24Est. Oct 2009
VIVUS
VIVUSCA - Campbell
1 program
1
VI-0521Phase 21 trial
Active Trials
NCT00806260Completed80Est. May 2009
Human BioSciences
1
FBT-POPhase 1/21 trial
50% heart rate reserveN/A1 trial
BarriersN/A1 trial
Beta-D-GlucanN/A1 trial
Beverage OneN/A1 trial
+18 more programs
Active Trials
NCT04307212Completed41Est. Sep 2023
NCT03607526Completed32Est. May 2019
NCT00403689Completed11Est. Mar 2008
+19 more trials
Biocorp
1 program
1
Strath® Kräuterhefe OriginalPhase 1/21 trial
Active Trials
NCT03223987Completed26Est. Nov 2019
Pfizer
PfizerNEW YORK, NY
3 programs
3
Formulation APhase 11 trial
PF-07976016Phase 11 trial
PF-08653944Phase 11 trial
Active Trials
NCT05677867Completed20Est. Mar 2023
NCT06910839Terminated21Est. May 2025
NCT07400679Recruiting54Est. Sep 2026
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
120 mg orlistatPhase 1Small Molecule
OrlistatN/ASmall Molecule
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
AMG 133Phase 11 trial
AMG 133Phase 11 trial
Active Trials
NCT06976372Completed120Est. Dec 2024
NCT07310563Completed59Est. May 2025
Piramal Pharma
Piramal PharmaMumbai, India
1 program
1
P11187Phase 11 trial
Active Trials
NCT01874366Unknown96Est. Dec 2015
Medica Corp
Medica CorpMA - Bedford
1 program
1
Switch active lifestyles brought to you by MediaWisePhase 11 trial
Active Trials
NCT00685555Completed1,300Est. Dec 2006
Design Pharmaceuticals
1 program
1
Switch active lifestyles brought to you by MediaWisePhase 1
MediaPharma
1 program
1
Switch active lifestyles brought to you by MediaWisePhase 1
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
36 programs
InactivityN/A1 trial
No treatment givenN/A1 trial
No treatment givenN/A1 trial
No treatment givenN/A1 trial
No treatment is givenN/A1 trial
+31 more programs
Active Trials
NCT06240208Recruiting40Est. Dec 2026
NCT07141914Completed285,327Est. Dec 2025
NCT04972721Completed3,439Est. Aug 2025
+37 more trials
Angeles Therapeutics
Haas AvocadoN/A1 trial
Mixed Tree NutsN/A1 trial
Pediatric Obesity Weight Evaluation Registry (POWER) StudyN/A1 trial
Smartphone ApplicationN/A1 trial
Active Trials
NCT02953158Completed60Est. Dec 2017
NCT03159689Completed131Est. Dec 2020
NCT02121132Completed4,276Est. Jun 2024
+1 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
BI 456906PHASE_11 trial
SurvodutidePHASE_1Peptide1 trial
survodutidePHASE_1Peptide1 trial
Active Trials
NCT06200467Completed110Est. Oct 2025
NCT06564441Completed34Est. Jan 2026
NCT06492135Completed30Est. Apr 2025
Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
A form ArginineN/A1 trial
One form of arginineN/A1 trial
Active Trials
NCT02352740Completed32
NCT02354794Completed36Est. Sep 2014
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
Challenge! Small Group InterventionN/A
Machine Learning AlgorithmN/A1 trial
Active Trials
NCT02960386Completed184Est. Jul 2020
UNION therapeutics
Greek Childhood Obesity (GRECO) StudyN/A1 trial
PROTEIN Mobile AppN/A1 trial
Active Trials
NCT02102763Completed5,000Est. May 2009
NCT04829851Completed120Est. Dec 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
Internet Behavioral InterventionN/A1 trial
T-helper 2 (Th2) Cytokine Responses in Overweight/Obese SubjectsN/A1 trial
Active Trials
NCT02421406Completed50Est. Feb 2017
NCT02085759Completed46
GSK
GSKLONDON, United Kingdom
2 programs
OrlistatN/ASmall Molecule1 trial
120 mg orlistatPHASE_1Small Molecule1 trial
Active Trials
NCT01387243Completed80Est. Dec 2010
NCT01550926Completed48Est. Mar 2009
Temple Therapeutics
SNAPSHOTN/A1 trial
telemedicineN/A1 trial
Active Trials
NCT02029976Completed264Est. Aug 2019
NCT00373230Unknown320Est. Feb 2010
Rhythm Pharmaceuticals
2 programs
RM-493PHASE_11 trial
SetmelanotidePHASE_2Peptide1 trial
Active Trials
NCT02431442Completed57Est. Jan 2014
NCT01749137Completed74Est. Sep 2013
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Adolescent Mindful Eating GroupN/A1 trial
Active Trials
NCT02114190Completed66Est. Mar 2017
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Energy restrictionN/A1 trial
Active Trials
NCT02360787Completed80Est. Aug 2017
Epitomee Medical
Epitomee DeviceN/A1 trial
Active Trials
NCT03610958Completed78Est. Sep 2018
Genome & Company
Reading InformationN/A

+8 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novo NordiskCagrisema
Novo NordiskNNC0487-0111
Novo NordiskNNC0487-0111
Novo NordiskNNC0487-0111
Novo NordiskNNC0487-0111
Innovent BiologicsIBI362
Prevail TherapeuticsEloralintide
Novo NordiskCagrilintide
Prevail TherapeuticsEloralintide
Novo NordiskCagrilintide
Innovent BiologicsIBI362
Prevail TherapeuticsTirzepatide
Novo NordiskSemaglutide
Novo NordiskSemaglutide
Novo NordiskCagrilintide

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 35,837 patients across 50 trials

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Start: Jun 2026Est. completion: Jan 20281,400 patients
Phase 3Not Yet Recruiting

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Start: Apr 2026Est. completion: Jul 2028600 patients
Phase 3Not Yet Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Start: Apr 2026Est. completion: Aug 2028400 patients
Phase 3Recruiting

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Start: Apr 2026Est. completion: Aug 2028630 patients
Phase 3Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Start: Apr 2026Est. completion: Jul 2028400 patients
Phase 3Not Yet Recruiting

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Start: Apr 2026Est. completion: Apr 2027336 patients
Phase 3Not Yet Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Start: Feb 2026Est. completion: Jul 2028900 patients
Phase 3Recruiting

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Start: Jan 2026Est. completion: Sep 2033460 patients
Phase 3Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Start: Dec 2025Est. completion: Feb 20281,035 patients
Phase 3Recruiting

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Start: Nov 2025Est. completion: Jun 2027330 patients
Phase 3Active Not Recruiting

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Start: May 2025Est. completion: Jun 2027470 patients
Phase 3Recruiting

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Start: Sep 2023Est. completion: Jan 2026441 patients
Phase 3Completed

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Start: Sep 2023Est. completion: May 2025242 patients
Phase 3Completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Start: May 2023Est. completion: Jan 2025200 patients
Phase 3Completed

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Start: Feb 2023Est. completion: Feb 20251,200 patients
Phase 3Completed

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

Start: Oct 2022Est. completion: May 2024307 patients
Phase 3Completed

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Start: Dec 2020Est. completion: Aug 2022375 patients
Phase 3Completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Start: Dec 2019Est. completion: Jul 20242,539 patients
Phase 3Completed

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Start: Oct 2019Est. completion: Mar 2022201 patients
Phase 3Completed

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Start: Sep 2019Est. completion: May 2021338 patients
Phase 3Completed

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

Start: Jan 2019Est. completion: Nov 2020401 patients
Phase 3Completed

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Start: Oct 2018Est. completion: Jun 202317,604 patients
Phase 3Completed

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Start: Oct 2018Est. completion: Mar 2021304 patients
Phase 3Completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Start: Aug 2018Est. completion: Apr 2020611 patients
Phase 3Completed

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Start: Feb 2026Est. completion: Feb 2027333 patients
Phase 2Recruiting

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Start: Oct 2025Est. completion: Dec 2026224 patients
Phase 2Active Not Recruiting
NCT06926842ParexelPetrelintide

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Start: Apr 2025Est. completion: Aug 2026221 patients
Phase 2Active Not Recruiting

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Start: Feb 2023Est. completion: Oct 2026140 patients
Phase 2Active Not Recruiting

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Start: Mar 2019Est. completion: Mar 2021706 patients
Phase 2Completed
NCT02949115Colorado Therapeutics70 mL red beetroot juice

Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances

Start: Nov 2016Est. completion: Jun 201915 patients
Phase 2Unknown

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

Start: Jan 2013Est. completion: Sep 201374 patients
Phase 2Completed
NCT00974831AbbottAmino Acid Drink Mixture

Glucose Tolerance in Healthy Overweight Adults

Start: Jul 2009Est. completion: Oct 200924 patients
Phase 2Completed

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

Start: Dec 2008Est. completion: May 200980 patients
Phase 2Completed
NCT00673387AstraZenecapramlintide acetate

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Start: Apr 2008Est. completion: Oct 2009636 patients
Phase 2Completed
NCT00402077AstraZenecapramlintide acetate

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Start: Nov 2006Est. completion: Aug 2007258 patients
Phase 2Completed
NCT00392925AstraZenecapramlintide acetate 360 mcg

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Start: Oct 2006Est. completion: Sep 2007177 patients
Phase 2Completed
NCT00444561AstraZenecapramlintide acetate

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Start: Aug 2004Est. completion: May 2005184 patients
Phase 2Completed
NCT03223987BiocorpStrath® Kräuterhefe Original

Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women

Start: May 2017Est. completion: Nov 201926 patients
Phase 1/2Completed

Parent-Based Treatment for Pediatric Overweight

Start: Sep 2008Est. completion: Jun 201377 patients
Phase 1/2Completed

Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes

Start: Apr 2026Est. completion: Dec 202780 patients
Phase 1Recruiting

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

Start: Mar 2026Est. completion: Jan 2028120 patients
Phase 1Recruiting

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Start: Feb 2026Est. completion: Jan 202796 patients
Phase 1Recruiting
NCT07411560Novo NordiskGlucose-dependent Insulinotropic Polypeptide

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Start: Feb 2026Est. completion: Jan 2027100 patients
Phase 1Recruiting

A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity.

Start: Feb 2026Est. completion: Sep 202654 patients
Phase 1Recruiting

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Start: Nov 2025Est. completion: Dec 202684 patients
Phase 1Recruiting

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

Start: Oct 2025Est. completion: Dec 202559 patients
Phase 1Completed

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

Start: Aug 2025Est. completion: Dec 202536 patients
Phase 1Completed

A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

Start: Aug 2025Est. completion: Oct 2025100 patients
Phase 1Completed
NCT06916065Prevail TherapeuticsEloralintide and Tirzepatide

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Start: Apr 2025Est. completion: Jan 2026188 patients
Phase 1Completed

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Start: Mar 2025Est. completion: May 202521 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
13 actively recruiting trials targeting 35,837 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.